Texas Children’s Hospital Center for Vaccine Development (CVD)

Recombinant Protein COVID-19 Vaccine Technology

Since 2011, the BCM-Texas Children’s CVD has been developing recombinant protein coronavirus vaccines for SARS and MERS, and in 2020 developed the first recombinant protein COVID-19 through microbial fermentation in yeast.  The technology has been transferred to 4 entities to date: India (Biological E, CORBEVAX), Indonesia (BioFarma), Bangladesh (Incepta) and Botswana (ImmunityBio). In India, through Biological E and the Indian Government, more than 70 million doses of CORBEVAX have been administered to adolescents in India.  CORBEVAX has also been authorized as an adult heterologous booster.  To date there are 8 scientific publications about laboratory development of the BCM-Texas Children’s CVD recombinant protein COVID-19 vaccine (in addition to 5 others on SARS/MERS (not shown), and 3 on the clinical trials see below):

The published results from the clinical trials performed by Biological E Ltd. can be found in the following articles and Medrxiv Preprints: